Avonex Growth In Second Qtr At Biogen
US biopharmaceutical company Biogen has announced growth in the secondquarter of 1997, driven by sales of Avonex (interferon beta-1a), the firm's treatment for multiple sclerosis.
Biogen's net income in the quarter ended June 30 was $19.9 million, compared with a net loss a year earlier of $9.1 million. Earnings per share were 26 cents, compared with a loss per share of 13 cents in the second quarter of 1996.
Sales in the quarter were $97.6 million, up 115%. Of this figure, $56.4 million was generated by Avonex. In the USA, the product is said to be maintaining its market leadership position, despite increased competition, according to Biogen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze